Enhanced birth tissue allografts and methods of manufacture

A two-step decellularization process for birth tissue allografts enhances the availability and release rates of growth factors and ECM, addressing the limitations of current methods by maintaining high biological activity and bioavailability.

WO2026044144A1 Publication Date: 2026-02-26ORBIO INNOVATIONS LLC
4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/043031
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-08-21
Filing Date
2025-08-21
Publication Date
2026-02-26

AI Technical Summary

Technical Problem

Current methods for processing birth tissue allografts, such as amniotic membrane and placental connective tissue matrix, result in reduced availability and delayed release of beneficial compounds like growth factors and extracellular matrix (ECM), leading to diminished biological activity and bioavailability.

Method used

A two-step decellularization process involving gentle decellularization solutions followed by neutralization to a pH of 4-8, combined with size reduction techniques, maintains high levels of growth factors and ECM, enhancing their solubility and release rates.

Benefits of technology

The method produces allografts with increased solubility and bioavailability of growth factors and ECM, allowing for immediate and delayed release based on application needs, improving soft tissue healing efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are a method of processing human birth tissue to create a variety of tissue forms that maintain high levels of beneficial compounds and increase tissue availability. Also provided are products made from the processed tissue forms, and application of these products in soft tissue repair and the treatment of wounds.
Need to check novelty before this filing date? Find Prior Art